812
0 Kommentare
Sobi exercises opt-in right for Elocta(TM) - Seite 3
For more information please contact
Sobi
Media Contact:
Charlotte af Klercker
T: +46 70 7 297 327
charlotte.afklercker@sobi.com
Investor Relations contact:
Jörgen Winroth
T: +1 347-224-0819, +1 212-579-0506
jorgen.winroth@sobi.com
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire
Lesen Sie auch
HUG#1873208
Aktuelle Themen
Verfasst von GlobeNewswire
1 im Artikel enthaltener WertIm Artikel enthaltene Werte